Transgenic Analysis of Human Drug–Metabolizing Enzymes: Preclinical Drug Development and Toxicology

Table 3.

Cytochrome P450 Gene Deletions

P450 Constitutive Phenotype Genetic Background Comments Citation
CYP1A1 None 129xC57BL/6 Protection against BaP toxicity (4)
CYP1A2 Respiratory distress 129xC57BL/6 Disruption of exon 2 Incomplete penetrance (6, 10)
None 129xCF-1 Disruption of exon 2, removal of exons 3–5
Deficient zoxazolamine metabolism
CYP1B1 None 129xC57BL/6 Protection against DMBA-induced bone marrow cytotoxicity and ovarian cancer (11)
CYP2E1 None 129xC57BL/6 Resistant to acetaminophen, chloroform and carbon tetrachloride hepatotoxicity (12)
CPR (liver-specific)[HRN™] Altered hepatic lipid homeostasis 129xC57BL/6 C57BL/6 No hepatic P450 function, altered drug pharmacokinetics, reduced acetaminophen toxicity (23, 26)
CYP7A1 Lethal in postnatal period (<18d) 129xC57BL/6 Rescued by dietary supplementation Alternative bile acid biosynthetic pathway induced (14, 15)
CYP19 Females infertile Precocious follicular depletion 129xC57BL/6 Disruption of exon 9 Partial rescue with estradiol treatment (17)
Females infertile Corpora lutea absent 129xC57BL/6 Disruption of exon 9 Enlargement of prostate gland Increased adiposity (16)
CYP26A1 Embryonic lethal, mid-late gestation 129xC57BL/6 Deletion of exons 2–6 Spina bifida, sirenomelia, caudal truncation (18)
Lethal in perinatal period (<24h) 129xC57BL/6 Deletion of entire gene Caudal truncation, vertebra transformation, hindbrain mispatterning (19)

This Article

  1. MI September 2003 vol. 3 no. 6 331-343